Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 and Irinotecan in Advanced Gastric Cancer
NCT00343668Phase 2Unknown
- Sponsor
- Korean Cancer Study Group
- Start
- Sep 2005
- Primary completion
- Mar 2007
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tegafur, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in gastric cancer (GC), sponsored by Korean Cancer Study Group. Status: unknown.
02
Drugs
tegafuririnotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00343668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00343668.